Global Alzheimer’s Therapeutics Market Is Expected To Reach USD 14,856.3 Mn By 2022 – Credence Research
The latest market report published by Credence Research, Inc. “Global Alzheimer’s Therapeutics Market – Growth, Share, Opportunities, Pipeline Analysis, Competitive Analysis, and Forecast, 2016 – 2022,” the Alzheimer’s therapeutics market was valued at USD 8,524.9 Mn in 2015, and is expected to reach USD 14,856.3 Mn by 2022, expanding at a CAGR of 8.02% from 2016 to 2022.
Market Insights
Alzheimer’s disease is a progressive and currently incurable disease, and potential or supportive treatments have only emerged in the last decade. However, the currently available treatments are lacking in terms of efficacy or target-specificity.
Browse the full report Alzheimer’s Therapeutics Market – Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 – 2022 report at http://www.credenceresearch.com/report/alzeimers-therapeutic-market
There are two types of drug classes used in treatment of Alzheimer’s disease, acetylcholinesterase (ACE) inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonist. ACE inhibitors constitute of galantamine hydrochloride, donepezil hydrochloride and rivastigmine; NMDA receptor antagonist includes mematidine hydrochloride. Since the discovery of what plaques and tangles comprised in Alzheimer’s – amyloid β (Aβ) peptide and hyperphosphorylated tau (p-tau) protein respectively.
An immense research and development has been carried out to develop therapeutics which can limit the rate of synthesis, reduce the toxicity or clear these factors from the brain. However, these attempts have been largely unsuccessful. Hence, considering the continuously rising Alzheimer prevalent population, as well as limited drugs available for treatment, Alzheimer’s disease presents a lucrative opportunity for an effective disease-modifying therapy to enter the market.
Pipeline Analysis
The phase III drugs included in the pipeline analysis are ENA713 (Novartis Pharmaceuticals), Flutemetamol (18F) (GE Healthcare), LY450139 (Eli Lilly and Company), Dimebon (Medivation, Inc. & Pfizer, Inc.), and Aripiprazole/ BMS-337039 (Otsuka Pharmaceutical, Inc.). The overall pipeline for Alzeihmer’s is still very much dominated by small molecule drugs.
However, there is still a considerable number of biologics in the pipeline with total 86 molecules, represented across all stages of development. According to market experts, the diversity of the several molecule types in the biologic group shows a certain level of innovation, with newer avenues being explored in accounts of recent failures. Overall, late stage clinical trials have highlighted very few molecules that could potentially replace current treatments during the forecast period.
Browse the full report Alzheimer’s Therapeutics Market – Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 – 2022 report at http://www.credenceresearch.com/report/alzeimers-therapeutic-market
Key Market Movements:
Market experts suggest that a family history of Alzheimer’s increases the risk of disease development by 7.5 times
The incidence and prevalence of Alzheimer’s disease doubles every five years after age 65 years
Currently population of developed countries is at high risk of Alzheimer due to increasing geriatric population
In developing countries from Asia Pacific and Latin America the awareness related to age-specific diseases such as dementia or Alzheimer is increasing
Latest Reports:
About Us:
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.
Who we are
Credence Research is a worldwide firm, containing more than 15 research consultants and almost 100 research and information professionals.
Our customers mirror our worldwide nature. Around 45% are in Europe, 30% in the Americas, 13% in Asia Pacific and 12% in the Middle East and Africa.
Our firm is intended to work as one. We are a solitary global research organization united by a solid arrangement of qualities, concentrated on customer effect.
What we do
We serve customers at each level of their organization, in whatever limit we can be most helpful, whether as a trusted counsel to top management or as a hands-on mentor for forefront representatives. For each engagement, we collect a group with the most suitable experience and ability.
No matter the challenge, we concentrate on delivering functional and persevering results, and preparing our customers to develop and lead. We join forces with customers to place suggestions into practice. Our research specialist work straightforwardly with customers over long stretches to create workforce aptitudes, drive operational change, and apply new working strategies.
Contact:
Name: Chris Smith
Designation: Global Sales Manager
E-mail: sales@credenceresearch.com
Ph: 1-800-361-8290
Web: Credence Research
The post Global Alzheimer’s Therapeutics Market Is Expected To Reach USD 14,856.3 Mn By 2022 – Credence Research appeared first on PDF Devices – eReaders and Tablets.
ReleaseID: 3593
Copyright © 1999-2013 SproutNews.com
